Brookline Capital Markets Forecasts XFOR FY2030 Earnings

Key Points

• Brookline Capital Markets raised its FY2030 EPS forecast for X4 Pharmaceuticals to $3.19 from $2.86. The estimate contrasts with a consensus forecast of a $0.68 loss per share for the current fiscal year.
• X4 reported quarterly EPS of a $0.16 loss, slightly better than analysts’ $0.17 loss estimate, and revenue of $2.88 million versus a $2.78 million consensus.
• Analyst sentiment was mixed but averaged a “Moderate Buy,” with a stated average price target of $11.25; company insiders sold 83,779 shares over the past 90 days.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Research analysts at Brookline Capital Markets lifted their FY2030 earnings per share estimates for X4 Pharmaceuticals in a report released on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of $3.19 per share for the year, up from their previous forecast of $2.86. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.68) per share.

Separately, Weiss Ratings raised X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, November 3rd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, X4 Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $11.25.

X4 Pharmaceuticals Stock Performance

XFOR opened at $3.18 on Monday. The stock has a market cap of $315.30 million, a PE ratio of -4.75 and a beta of 0.47. The company has a current ratio of 13.22, a quick ratio of 12.86 and a debt-to-equity ratio of 0.55. X4 Pharmaceuticals has a 1 year low of $2.43 and a 1 year high of $4.83. The stock's 50 day simple moving average is $3.23 and its 200-day simple moving average is $3.78.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. X4 Pharmaceuticals had a negative return on equity of 49.62% and a negative net margin of 474.74%. The company had revenue of $2.88 million during the quarter, compared to the consensus estimate of $2.78 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in XFOR. Russell Investments Group Ltd. grew its holdings in shares of X4 Pharmaceuticals by 2,871.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company's stock worth $618,000 after purchasing an additional 206,080 shares during the last quarter. Alps Advisors Inc. increased its position in shares of X4 Pharmaceuticals by 36.2% during the 3rd quarter. Alps Advisors Inc. now owns 130,424 shares of the company's stock worth $378,000 after purchasing an additional 34,698 shares in the last quarter. WINTON GROUP Ltd lifted its holdings in X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company's stock valued at $67,000 after purchasing an additional 3,800 shares during the last quarter. Squarepoint Ops LLC bought a new position in X4 Pharmaceuticals during the 2nd quarter valued at about $313,000. Finally, AXQ Capital LP bought a new position in X4 Pharmaceuticals during the 2nd quarter valued at about $107,000. 72.03% of the stock is owned by institutional investors.

Insider Transactions at X4 Pharmaceuticals

In related news, Chairman Adam Craig sold 47,436 shares of the business's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the sale, the chairman owned 328,651 shares of the company's stock, valued at $1,459,210.44. The trade was a 12.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President John Volpone sold 24,576 shares of the business's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $109,117.44. Following the completion of the sale, the president directly owned 265,305 shares in the company, valued at approximately $1,177,954.20. This represents a 8.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 83,779 shares of company stock valued at $353,387. Corporate insiders own 1.13% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company's research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.